ADDUS HOMECARE CORP (ADUS)

Sector: Health Care

    Home/Companies/ADUS/Annual Meeting

2026 Annual Meeting Analysis

ADDUS HOMECARE CORP · Meeting: June 10, 2026

Policy v1.2medium confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

0

Directors AGAINST

2

Say on Pay

AGAINST

Auditor

FOR

Director Elections

Election of Class II Directors

/2 AGAINST

Against Analysis

✗ AGAINST
Michael Earley3-year TSR underperformance vs peer group exceeds threshold: ADUS -13.6% vs peer median +34.4%, gap of -48.0pp exceeds 20pp threshold for negative absolute TSR5-year TSR mitigant does not rescue: ADUS 5-year return -12.0% vs peer median -12.8%, gap of +0.8pp — 5-year performance is adequate (does not exceed 20pp threshold), triggering mitigant downgrade to FOR

Mr. Earley has served since 2014, giving him full overlap with the 3-year underperformance period; ADUS stock fell 13.6% over three years while the company's own compensation peer group gained 34.4% on average, a gap of 48 percentage points that far exceeds the 20-point trigger for companies with negative absolute returns — however, the 5-year record shows ADUS at -12.0% versus the peer median of -12.8%, a gap of only +0.8pp that does not exceed the 20pp threshold, so the policy's 5-year mitigant applies and the vote is downgraded from AGAINST to FOR, indicating the recent 3-year trough appears to be a short-term deviation from an otherwise adequate longer-term track record.

✗ AGAINST
Veronica Hill-Milbourne3-year TSR underperformance vs peer group exceeds threshold: ADUS -13.6% vs peer median +34.4%, gap of -48.0pp exceeds 20pp threshold for negative absolute TSR5-year TSR mitigant does not rescue: ADUS 5-year return -12.0% vs peer median -12.8%, gap of +0.8pp — 5-year performance is adequate (does not exceed 20pp threshold), triggering mitigant downgrade to FOR

Ms. Hill-Milbourne joined in January 2021, giving her meaningful overlap with the 3-year underperformance period; the same 48-percentage-point gap versus peer median triggers a No vote — however, applying the 5-year mitigant, the 5-year gap of +0.8pp does not exceed the 20pp threshold, so the vote is downgraded to FOR, reflecting that the underperformance appears recent rather than sustained across her full tenure.

For Analysis

Both Class II nominees (Earley and Hill-Milbourne) initially trigger an AGAINST vote due to severe 3-year stock underperformance — ADUS declined 13.6% while its compensation peer group gained 34.4%, a 48-percentage-point gap far exceeding the 20pp policy threshold for companies with negative absolute returns. However, the 5-year mitigant applies to both directors: over five years, ADUS returned -12.0% versus the peer median of -12.8%, a gap of only +0.8pp that does not breach the 20pp threshold. Per policy, when the 5-year relative performance is adequate, the vote is downgraded from AGAINST to FOR, indicating the recent underperformance is a short-term development within an otherwise acceptable long-term track record. Both directors receive a FOR vote.

Say on Pay

✗ AGAINST

CEO

R. Dirk Allison

Total Comp

$12,190,449

Prior Support

overwhelming majority%

CEO total compensation of $12,190,449 includes a $6,017,895 special retention stock grant on top of regular performance equity, resulting in stock awards of $9,767,870 in a single year — materially above expected benchmark levels for a $1.8B healthcare services company CEOVariable pay above benchmark driven in part by a large special one-time retention grant; company's 3-year stock return is -13.6% versus peer median of +34.4%, a gap of 48pp — pay-for-performance alignment failsAnnual incentive plan uses single metric (Adjusted EBITDA only) with no multi-year or TSR-based performance condition for equity; restricted stock vests on time only, not on stock price outcomes

CEO R. Dirk Allison received total compensation of $12,190,449 in 2025, driven primarily by $9,767,870 in stock awards — including a special retention grant of 63,500 shares valued at approximately $6 million on top of regular performance equity — which is substantially above the expected range for a CEO at a $1.8 billion healthcare services company and triggers the individual CEO threshold under the policy. Beyond the pay level concern, the pay-for-performance alignment check fails: Addus shareholders lost 13.6% over three years while the company's own peer group gained an average of 34.4%, yet above-benchmark variable pay was awarded, indicating the incentive structure is not working as intended. Additionally, the company's equity grants vest based solely on time after meeting an Adjusted EBITDA threshold — with no multi-year stock performance condition — meaning awards function more like deferred salary than true performance pay, which the policy flags as a concern about pay quality.

Auditor Ratification

✓ FOR

Auditor

PricewaterhouseCoopers LLP

Tenure

N/A

Audit Fees

N/A

Non-Audit Fees

N/A

The proxy filing does not include an auditor fee table with specific audit and non-audit fee amounts, and auditor tenure is not explicitly disclosed in the provided filing text; with no fee ratio trigger calculable and no confirmed tenure of 25 or more years, no policy threshold fires, and PricewaterhouseCoopers is a Big 4 firm fully appropriate for a $1.8 billion company, so the default FOR vote applies.

Overall Assessment

The 2026 Addus HomeCare annual meeting presents three standard proposals: both Class II director nominees initially trigger the TSR underperformance threshold due to a severe 48-percentage-point lag versus peers over three years, but the 5-year mitigant applies and both receive FOR votes reflecting adequate longer-term performance; the Say on Pay vote receives an AGAINST recommendation due to above-benchmark CEO compensation driven by a large special retention grant combined with significant stock underperformance versus peers, and an equity program that lacks meaningful long-term stock price conditions. The auditor ratification receives a FOR vote as no fee or tenure data was available to trigger a policy threshold and PwC is an appropriate Big 4 auditor for the company's size.

Filing date: April 23, 2026·Policy v1.2·medium confidence

Compensation Peer Group

13 companies disclosed in 2026 proxy filing

AMEDAmedisys, Inc.
AVAHAveanna Healthcare Holdings, Inc.
CHEChemed Corporation
EHABEnhabit, Inc.
MODVModivCare Inc.
NHCNational HealthCare Corporation
OPCHOption Care Health, Inc.
MDPediatrix Medical Group, Inc.
RDNTRadNet, Inc.
SEMSelect Medical Holdings Corporation
ENSGThe Ensign Group, Inc.
PNTGThe Pennant Group, Inc.
USPHU.S. Physical Therapy, Inc.